加味己椒苈黄汤治疗终末期心力衰竭患者的临床效果

doi:10.20047/j.issn1673-7210.2023.02.11

Abstract
Figure/Table
References (28)
Related Citation (2)

Download: PDF (570 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Jiawei Jijiao Lihuang Decoction on patients with end-stage heart failure, and the effects on left ventricular ejection fraction (LVEF) , N-terminal B-type natriuretic peptide (NT -proBNP), and hospitalization period. Methods A total of 62 patients with end-stage heart failure admitted to the Department of Cardiology, Shuyang County Hospital Affiliated to Nanjing University of Chinese Medicine from December 2018 to April 2021 were selected and they were divided into the traditional Chinese medicine group (31 cases) and the control group (31 cases) by random number table method. The control group was treated with the standard drug therapy recommended by the guideline, while the Chinese medicine group was treated with Jiawei Jijiao Lihuang Decoction on the basis of the standard drug therapy. The treatment period was seven days. Plasma NT-proBNP, LVEF, traditional Chinese medicine syndrome score, hospitalization period, liver and kidney function, electrolytes and blood routine were observed before and after treatment in both groups. Results After 7 days of treatment, the clinical efficacy of the traditional Chinese medicine group was better than that of the control group, and the difference was statistically significant (P＜0.05). There was no significant difference in the scores of traditional Chinese medicine symptoms, NT-proBNP and LVEF between the two groups before treatment (P＞0.05); after treatment, traditional Chinese medicine syndrome scores in both groups were lower than before treatment, and traditional Chinese medicine group was lower than control group (P＜0.05). After treatment, NT-proBNP in both groups was lower than that before treatment, and the traditional Chinese medicine group was lower than that in control group (P＜0.05). After treatment, LVEF in both groups was higher than that before treatment, and the traditional Chinese medicine group was higher than that in control group (P＜0.05). The duration of hospitalization in traditional Chinese medicine group was shorter than that in control group (P＜0.05). There was no significant difference in liver and kidney function electrolyte, blood routine and other safety indexes between two groups (P＞0.05). Conclusion Jijiao Lihuang Decoction is effective in improving the clinical symptoms and signs of patients with end-stage heart failure, decreasing the level of NT-proBNP, increasing LVEF, and shortening the period of hospitalization. It has a definite curative effect and no obvious adverse reaction, it can use Jijiao Lihuang decoction for clinical reference.

Key words： Jiawei Jijiao Lihuang Decoction End-stage Heart Failure N-terminal B-type natriuretic peptide

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Dongsheng1 SUN Jing2

Cite this article:

ZHAO Dongsheng1 SUN Jing2. Clinical effect of Jiawei Jijiao Lihuang Decoction on patients with end-stage heart failure[J]. 中国医药导报, 2023, 20(2): 52-55.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.02.11 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I2/52

[1] Yancy CW，Jessup M，Bozkurt B，et al. 2013 ACCF/AHAguideline for the management of heart failure：executivesummary：a report of the American College of Cardiology Foundation / American Heart Association Task Force on prac-tice guidelines [J]. Circulation，2013，128（16）：1810-1852.
[2] 刘琦，孙丽丽，庞占琪，等.重组人脑利钠肽联合稳心颗粒治疗终末期心力衰竭的效果和对血流动力学及血管内皮功能的影响[J].中国医药导报，2021，18（8）：66-69.
[3] 陈楠楠，薛一涛.中药干预慢性心力衰竭线粒体能量代谢的研究进展[J].世界中医药，2022，17（3）：437-440.
[4] 中华医学会心血管病分会、中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：769-789.
[5] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：77-85.
[6] 李乾构，沈绍功，栗德林.今日中医内科[M].北京：人民卫生出版社，2011：121-122.
[7] Badve MS，Zhou Z，van de Beek D，et al. Frequency ofpost- stroke pneumonia：systematic review and meta -analysis of observational studies [J]. Int J Stroke，2019，14（2）：125-136.
[8] Chung M，Bernheim A，Mei X，et al. CT imaging featuresof 2019 novel coronavirus（2019-nCoV）[J]. Radiology，2020， 295（1）：202-207.
[9] Aissaoui N，Morshuis M，Maoulida H，et al. Management of end-stage heart failure patients with or without ventricular assist device： an observational comparison of clinical and economic outcomes [J]. Eur J Cardiothorac Surg，2018，53（1）： 170-177.
[10] Paluszkiewicz L，Kukulski T，Zembala M，et al. The role of long-term mechanical circulatory support in the treatment of end-stage heart failure [J]. Kardiol Pol，2019，77（3）：331-340.
[11] 郭玉娜，陈丽名，刘坤.经方在心力衰竭中的临床应用[J].中国医药导报，2022，19（30）：116-119.
[12] 何泽慧，张戈，欧爱华.关于中医临床疗效评价研究的思考[J].中国民族民间医药，2020，29（1）：115-118.
[13] 宋晓龙，宋俊，潘仁友，等.利心水方联合常规西药治疗冠心病心力衰竭的临床效果[J].中国医药导报，2022， 19（11）：68-72.
[14] 张秋，何德英，任毅，等.参芪强心汤治疗慢性心力衰竭的临床研究[J].中国中医急症，2019，28（1）：88-90，105.
[15] 欧阳嘉慧，张淼，王娅，等.中药治疗心力衰竭合并心律失常的系统评价再评价[J].时珍国医国药，2021，32（5）：1272-1276.
[16] 王丽新，彭飞乔，程荣歧，等.己椒苈黄汤对慢性肺源性心脏病患者肺动脉高压的影响[J].中西医结合心脑血管病杂志，2014，12（6）：651-652.
[17] 张国顺，白义萍，王小兰，等.葶苈子抗心衰有效组分筛选及其作用机制分析[J].中国实验方剂学杂志，2017， 23（4）：118-125.
[18] 胡晓玲，付蓉，苏治福.防己黄芪汤治疗慢性心力衰竭作用机制的网络药理学探讨[J].中西医结合心脑血管病杂志，2021，19（22）：3844-3852.
[19] 年婧，景军强，赵重博，等.椒目仁油微波-超声辅助提取工艺优化及降血脂活性研究[J].成都中医药大学学报，2021，44（4）：54-61.
[20] 王玉，杨雪，夏鹏飞，等.大黄化学成分、药理作用研究进展及质量标志物的预测分析[J].中草药，2019，50（19）：4821-4837.
[21] 金丽霞，金丽军，栾仲秋，等.大黄的化学成分和药理研究进展[J].中医药信息，2020，37（1）：121-126.
[22] 高刻，杨君，徐华建.沙库巴曲缬沙坦钠片对心力衰竭合并低钠血症患者心室重构的影响[J].中国医药导报，2022，19（11）：77-80.
[23] 王一鸣，任珂.血清NT-proBNP sST2 AngⅡ水平对慢性心功能不全危险分层及预后的评估价值[J].安徽医学，2021，42（10）：1162-1166.
[24] 沈青青，张欣欣，王计亮.急性心力衰竭并发肾功能恶化患者血乳酸和NT-proBNP的表达及其对肾功能恶化的预测价值[J].中国医药导报，2022，19（26）：62-66.
[25] 孙芸，张婷婷，张燚.血浆sST2联合NT-proBNP对急诊心力衰竭患者生存状况的预测价值[J].临床和实验医学杂志，2020，19（8）：849-852.
[26] 王琼.动脉血乳酸、降钙素原及NT-proBNP对体外循环心脏手术患者评估中的应用[J].中国医药科学，2020， 10（11）：116-119.
[27] 管浩，崔锦钢，袁建松，等.左心室射血分数减低患者冠状动脉慢性完全闭塞病变介入治疗的安全性及远期疗效[J].中国循环杂志，2021，36（10）：953-960.
[28] 褚国洁，张立晶，李蒙，等.慢性心力衰竭患者左心室射血分数与血尿酸和N末端B型脑钠肽前体等指标的关系[J].中国医药，2021，16（8）：1150-1153.